At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 16, 2026 at 07:05 ET
CytomX Therapeutics reported financial results for 2025, highlighted by a significant revenue decline to $76.2 million from $138.1 million in 2024, driven by the completion of collaboration milestones. However, the company announced positive Phase 1 data for its Varseta-M ADC in colorectal cancer and extended its cash runway into Q2 2027. Despite advancing its pipeline, including upcoming combination data for CX-801 with KEYTRUDA®, the sharp drop in revenue and net loss of $17.4 million weigh on near-term fundamentals.
- Revenue dropped to $76.2 million in 2025 from $138.1 million in 2024, primarily due to completion of performance obligations with Bristol Myers Squibb and reduced collaboration progress with Moderna, Astellas, and Regeneron.
- Net loss was $17.37 million in 2025 compared to net income of $31.87 million in 2024.
- Cash, cash equivalents, and investments totaled $137.1 million as of December 31, 2025, providing a cash runway into Q2 2027.
- Positive Phase 1 dose expansion data reported for Varseta-M in advanced colorectal cancer; FDA interactions planned for mid-2026 to align on registrational trial design.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access